Cover Image

Analytical and clinical validation of Alzheimer's disease blood biomarkers with a focus on plasma p‐tau217

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Fernando Gonzalez‐Ortiz, Thomas K. Karikari, Kaj Blennow
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alzheimer's & Dementia
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Biofluid‐based biomarkers for tau pathophysiology in Alzheimer's disease
by: Henrik Zetterberg, et al.
Published: (2025)

Neurodegeneration and acute neuronal injury drastically skew the p‐tau217/non‐p217 ratio in both CSF and plasma regardless of analytical technique – a mass spectrometry and Simoa study
by: Kaj Blennow
Published: (2024)

A novel cross‐species p ‐tau217 immunoassay for investigating animal models of Alzheimer's disease
by: Alberto González‐Mayoral, et al.
Published: (2025)

Cerebrospinal Fluid Soluble Tau aggregates as a Biomarker for Alzheimer’s disease
by: Md Tohidul Islam, et al.
Published: (2025)

The plasma p‐tau217/BD‐tau ratio improves biomarker short‐term variability in memory clinic patients
by: Frederikke Kragh Clemmensen, et al.
Published: (2025)

Plasma p‐tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease
by: Przemysław R. Kac, et al.
Published: (2025)

Repeated plasma p‐tau217 measurements to monitor clinical progression heterogeneity
by: Bjørn‐Eivind Kirsebom, et al.
Published: (2025)

Plasma p‐tau 217 and neurofilament/p‐tau 217 ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration
by: Alberto Benussi, et al.
Published: (2025)

Clinical value of novel blood‐based tau biomarkers in Creutzfeldt–Jakob disease
by: Giuseppe Mario Bentivenga, et al.
Published: (2024)

Novel Alzheimer’s disease blood‐based biomarkers in exercise trials
by: Thomas K Karikari, et al.
Published: (2024)

Pittsburgh plasma p‐tau217: Classification accuracies for autosomal dominant and sporadic Alzheimer's disease in the community
by: Anuradha Sehrawat, et al.
Published: (2025)

Correction to “Comparison of plasma p‐tau217/Aβ42, p‐tau217, and Aβ42/Aβ40 biomarkers by race to detect Alzheimer's disease”
Published: (2025)

Comparison of plasma p‐tau217 and Aβ42/Aβ40 biomarkers by race to detect Alzheimer’s disease
by: Katheryn A Q Cousins, et al.
Published: (2024)

Enhancing diagnostic precision in Alzheimer's disease: Impact of comorbidities on blood biomarkers for clinical integration
by: Makrina Daniilidou, et al.
Published: (2025)

Diagnostic accuracy of plasma p‐tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts
by: Jun Wang, et al.
Published: (2025)

Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome‐wide association studies
by: Jun Pyo Kim, et al.
Published: (2026)

Predicting cognitive decline with amyloid‐PET, plasma p‐tau217, Aβ42/40, and p‐tau217/Aβ42 in a community‐based cohort – relevance for clinical trial enrollment
by: Dario Bachmann, et al.
Published: (2025)

Disclosure of plasma p‐tau217 measure improves diagnostic confidence in patients with Alzheimer's disease versus syndromes associated with frontotemporal lobar degeneration
by: Valentina Cantoni, et al.
Published: (2025)

Plasma p‐tau217, NfL, GFAP diagnostic performance and biomarker profiles in Alzheimer's disease, frontotemporal dementia, and psychiatric disorders, in a prospective unselected neuropsychiatry memory clinic
by: Dhamidhu Eratne, et al.
Published: (2025)

Predicting onset of Alzheimer disease symptoms with a plasma %p‐tau217 clock
by: Kellen K. Petersen, et al.
Published: (2025)

Longitudinal plasma phosphorylated‐tau217 and other related biomarkers in a non‐demented Alzheimer's risk‐enhanced sample
by: Lianlian Du, et al.
Published: (2024)

Baseline plasma NfL, p‐tau217 and tau‐PET SUVr predict cognitive decline in non‐demented persons from a memory clinic
by: Augusto J. Mendes, et al.
Published: (2024)

Superiority of p‐tau217 among plasma biomarkers in diagnostic accuracy in non‐demented persons from the Geneva Memory Center cohort
by: Augusto J. Mendes, et al.
Published: (2024)

Neuroimaging correlates and biomarker performance of a fully automated plasma p‐tau217/Aβ42 ratio assay in a clinical cohort with Alzheimer's disease
by: Yoo Hyun Um, et al.
Published: (2025)

Influence of medical conditions on the diagnostic accuracy of plasma p‐tau217 and p‐tau217/Aβ42
by: Marcos Olvera‐Rojas, et al.
Published: (2024)

Biological staging of Alzheimer’s disease with the novel plasma eMTBR‐tau243 and % p ‐tau217
by: Gemma Salvadó, et al.
Published: (2025)

Plasma p‐tau217 and p‐tau217/Aβ1‐42 are effective biomarkers for identifying CSF‐ and PET imaging‐diagnosed Alzheimer's disease: Insights for research and clinical practice
by: Xiaomei Zhong, et al.
Published: (2025)

Technical and clinical validation of a novel plasma p‐tau217 assay: evaluation in real world population‐based and racially‐diverse cohorts
by: Anuradha Sehrawat, et al.
Published: (2024)

Impact of racialization on neuroimaging and plasma biomarkers of Alzheimer's disease
by: Alexandra Gogola, et al.
Published: (2025)

Early detection of subjective cognitive decline and Alzheimer's disease: Analytical validation of a newly developed pT217‐tau assay
by: Hash Brown Taha
Published: (2024)

Plasma p ‐tau 217 as a suitable biomarker for monitoring cognitive changes in Alzheimer’s disease
by: Davina Biel, et al.
Published: (2025)

Multivariate models using NULISAseq and plasma p‐tau217 for staging Alzheimer's disease
by: James D. Doecke, et al.
Published: (2025)

Discrimination tasks increase the value of plasma p ‐tau217 to predict presymptomatic Alzheimer's disease
by: Lara Huyghe, et al.
Published: (2025)

Discrimination tasks increase the value of plasma p ‐tau217 to predict presymptomatic Alzheimer's disease
by: Lara Huyghe, et al.
Published: (2025)

Diagnostic performance of plasma p‐tau217 and Aβ42/40 biomarkers in the outpatient memory clinic
by: Yoav D. Piura, et al.
Published: (2025)

Plasma p ‐tau changes across the clinical spectrum of Alzheimer's disease: a systematic review and meta‐analysis
by: Wagner S. Brum, et al.
Published: (2025)

The role of tau and amyloid pathology in neurosensory impairments during preclinical Alzheimer's disease
by: Daniel C Bowie, et al.
Published: (2025)

Clinical utility of plasma p‐tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease
by: Joyce R. Chong, et al.
Published: (2025)

Tau Aggregates in Cerebrospinal Fluid: A Promising Biomarker for Neurodegenerative Diseases
by: Md Tohidul Islam, et al.
Published: (2024)

Utility of plasma p‐tau217 as a secondary outcome for clinical trials across AD continuum
by: Pamela C.L. Ferreira, et al.
Published: (2024)